Pharmaceutical

Kronos mulls ‘strategic alternatives’ after axing cancer drug development

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.

Nov 15, 2024 - 06:00
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.
Read the original article

Tags:

Previous Article

Leading account and intent-based sales and marketing providers and technology so...

Next Article

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Hospital systems have to decide: Do they want to be Apple or Android?

Opinion: Hospital systems have to decide: Do they want ...

Nov 15, 2023

STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee

STAT+: Novartis claims Takeda is stonewalling efforts t...

Oct 26, 2023

Smoking impairs immune response, even after quitting, new study says

Smoking impairs immune response, even after quitting, n...

Feb 15, 2024